title: Up-regulation of KIF14 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in cervical cancer.
abstract: Kinesin family member 14 (KIF14) is a member of kinesin family proteins which have been found to be dysregulated in various cancer types. However, the expression of KIF14 and its potential prognostic significance have not been investigated in cervical cancer. Real-time PCR was performed to assess the expression levels of KIF14 in 47 pairs of cervical cancer tissues and their matched normal tissues from patients who had not been exposed to chemotherapy as well as tissue samples from 57 cervical cancer patients who are sensitive to paclitaxel treatment and 53 patients who are resistant. The association between KIF14 expression levels in tissue and clinicopathological features or chemosensitivity was examined. Kaplan-Meier analysis and Cox proportional hazards model were applied to assess the correlation between KIF14 expression levels and overall survival (OS) of cervical cancer patients. KIF14 expression levels were significantly increased in cervical cancer tissues compared with matched non-cancerous tissues and it was higher in tissues of patients who are chemoresistant compared with those who are chemosensitive. KIF14 expression was positively associated with high tumour stage (P=0.0044), lymph node metastasis (P=0.0034) and chemoresistance (P<0.0001). Kaplan-Meier analysis showed that high KIF14 expression levels predicted poor survival in patients with (P=0.0024) or without (P=0.0028) paclitaxel treatment. Multivariate analysis revealed that KIF14 was an independent prognostic factor for OS. Our study suggests that KIF14 may serve as a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in cervical cancer.
authors.affiliation: Jinan Second People's Hospital, No. 148 Jingyi Road, Jinan 250011, Shandong, China.
authors.forename: Wenjing
authors.initials: W
authors.lastname: Wang
authors.affiliation: Jinan Second People's Hospital, No. 148 Jingyi Road, Jinan 250011, Shandong, China.
authors.forename: Yanhua
authors.initials: Y
authors.lastname: Shi
authors.affiliation: The Second Hospital Affiliated to Shandong University of Traditional Chinese Medicine, No. 1 Jingba Road, Jinan 250001, Shandong, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Li
authors.affiliation: The Second Hospital Affiliated to Shandong University of Traditional Chinese Medicine, No. 1 Jingba Road, Jinan 250001, Shandong, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Cui
authors.affiliation: Jinan Second People's Hospital, No. 148 Jingyi Road, Jinan 250011, Shandong, China bazhiyang@sina.com.
authors.forename: Baozhi
authors.initials: B
authors.lastname: Yang
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000096:biosynthesis*; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D016547:Kinesins / Q000096:biosynthesis*; D008875:Middle Aged; D015513:Oncogene Proteins / Q000096:biosynthesis*; D017239:Paclitaxel / Q000008:administration & dosage*; D015996:Survival Rate; D015854:Up-Regulation; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality
chemical_list: D014408:Biomarkers, Tumor; D015513:Oncogene Proteins; C502598:KIF14 protein, human; D016547:Kinesins; D017239:Paclitaxel
keywords: KIF14; cervical cancer; chemoresistance; prognosis